Wait, don't miss out on the latest GovCon industry news!

Sign Up Now! ExecutiveBiz provides you with Daily Updates and News Briefings

*By clicking "Join us now" you agree to receive email, promotions and general messages from GovCon Wire, In addition, you also agree to GovCon Wire Privacy Policy and Terms & Conditions.

X Remind me Later

HHS Taps Profectus BioSciences for Ebola, Marburg Vaccine R&D

BiomedicalNIHThe Department of Health and Human Services has awarded Profectus BioSciences an $8.6 million contract to further develop and test a vaccine designed to treat infections caused by Ebola and Marburg viruses.

HHS said Tuesday the cost-plus-fixed-fee contract covers research and development of Profectus’ Ebola and Marburg filovirus vaccine rVSVN4CT1.

Profectus presented data from animal studies on the injectable drug at the Filovirus Medical Countermeasures Meeting hosted by the National Institutes of Health in Maryland last year.

The biotechnology firm said its rVSV‐based vaccines gave 100 percent protection to monkeys from Ebola and Marburg during government-backed research.

According to the company, the rVSV vaccine delivery vector is designed to trigger antibody responses in the surface glycoproteins of several infectious diseases as well as biothreat agents.

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles